Skip to main content
Acute radiation syndrome treatment gains Orphan Drug designation

The FDA granted Chrysalis BioTherapeutics' investigational candidate TP508, or rusalatide acetate, Orphan Drug status, indicated for acute radiation syndrome, or radiation sickness. A regenerative peptide drug, TP508 instigates revascularization and the repair of multiple tissues.

Full Story: